Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05407064 · ClinicalTrials.gov registry record · Phase 2
A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms
A Phase 2 study, sponsored by Definium Therapeutics US.
- Completed
- Registry status
- Phase 2
- Development phase
- 198
- Enrollment target
NCT05407064 is a Phase 2 study that has completed, run by Definium Therapeutics US. The registered enrollment target is 198 participants.
The verdict
NCT05407064, a Phase 2 study, has completed, sponsored by Definium Therapeutics US.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 198 participants
- Enrollment target
Study Summary
This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).
Interventions
- OTHER Placebo
- DRUG MM120
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 198 participants |
| Start Date | 2022-08-24 |
| Est. Completion | 2023-11-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05407064
The ClinicalTrials.gov registry entry for NCT05407064 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 198 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Definium Therapeutics US, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05407064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05407064 about?
NCT05407064 is a clinical study titled "A Dose-Finding Study of MM120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms". This is a Phase 2, multi-center, randomized, double-blind, parallel-group, dose-finding study to assess the effect of 4 doses of MM120 (25, 50, 100 or 200 μg freebase-equivalent) for the treatment of anxiety symptoms in subjects diagnosed with generalized anxiety disorder (GAD).
What is the current status of trial NCT05407064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 198 participants. The study started on 2022-08-24. Estimated completion is 2023-11-27.
What interventions are being tested in trial NCT05407064?
The interventions under investigation include: Placebo (OTHER), MM120 (DRUG).
Who is sponsoring clinical trial NCT05407064?
This trial is sponsored by Definium Therapeutics US, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.